These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 26232103)

  • 1. Negative Impact of Aromatase Inhibitors on Proximal Femoral Bone Mass and Geometry in Postmenopausal Women with Breast Cancer.
    Lee SJ; Kim KM; Brown JK; Brett A; Roh YH; Kang DR; Park BW; Rhee Y
    Calcif Tissue Int; 2015 Dec; 97(6):551-9. PubMed ID: 26232103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer.
    Hong AR; Kim JH; Lee KH; Kim TY; Im SA; Kim TY; Moon HG; Han WS; Noh DY; Kim SW; Shin CS
    Osteoporos Int; 2017 Apr; 28(4):1413-1422. PubMed ID: 28083668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial.
    Cheung AM; Tile L; Cardew S; Pruthi S; Robbins J; Tomlinson G; Kapral MK; Khosla S; Majumdar S; Erlandson M; Scher J; Hu H; Demaras A; Lickley L; Bordeleau L; Elser C; Ingle J; Richardson H; Goss PE
    Lancet Oncol; 2012 Mar; 13(3):275-84. PubMed ID: 22318095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. QCT of the proximal femur--which parameters should be measured to discriminate hip fracture?
    Museyko O; Bousson V; Adams J; Laredo J-; Engelke K
    Osteoporos Int; 2016 Mar; 27(3):1137-1147. PubMed ID: 26415934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of eldecalcitol, an active vitamin D analog, on hip structure and biomechanical properties: 3D assessment by clinical CT.
    Ito M; Nakamura T; Fukunaga M; Shiraki M; Matsumoto T
    Bone; 2011 Sep; 49(3):328-34. PubMed ID: 21605716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of aromatase inhibitor treatment on vertebral morphology and bone mineral density in postmenopausal women with breast cancer.
    Villa P; Lassandro AP; Amar ID; Vacca L; Moruzzi MC; Ferrandina G; Terribile D; Masetti R; Scambia G
    Menopause; 2016 Jan; 23(1):33-9. PubMed ID: 26308233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: A cross-sectional study.
    Pedersini R; Monteverdi S; Mazziotti G; Amoroso V; Roca E; Maffezzoni F; Vassalli L; Rodella F; Formenti AM; Frara S; Maroldi R; Berruti A; Simoncini E; Giustina A
    Bone; 2017 Apr; 97():147-152. PubMed ID: 28104509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive factors for the efficacy of denosumab in postmenopausal Japanese women with non-metastatic breast cancer receiving adjuvant aromatase inhibitors: a combined analysis of two prospective clinical trials.
    Nakatsukasa K; Koyama H; Ouchi Y; Sakaguchi K; Fujita Y; Matsuda T; Kato M; Konishi E; Taguchi T
    J Bone Miner Metab; 2019 Sep; 37(5):864-870. PubMed ID: 30868270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of DXA derived bone quality indexes and bone geometry parameters in early breast cancer patients: A single center cross-sectional study.
    Pedersini R; Cosentini D; Rinaudo L; Zamparini M; Ulivieri FM; di Mauro P; Maffezzoni F; Monteverdi S; Vena W; Laini L; Amoroso V; Simoncini EL; Farina D; Mazziotti G; Berruti A
    Bone Rep; 2023 Jun; 18():101654. PubMed ID: 36700242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density.
    Genant HK; Engelke K; Hanley DA; Brown JP; Omizo M; Bone HG; Kivitz AJ; Fuerst T; Wang H; Austin M; Libanati C
    Bone; 2010 Jul; 47(1):131-9. PubMed ID: 20399288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients.
    Lee SA; Hwang SH; Ahn SG; Lee HM; Jeong J; Lee HD
    Breast Cancer Res Treat; 2011 Dec; 130(3):863-70. PubMed ID: 21861101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proximal femoral density and geometry measurements by quantitative computed tomography: association with hip fracture.
    Cheng X; Li J; Lu Y; Keyak J; Lang T
    Bone; 2007 Jan; 40(1):169-74. PubMed ID: 16876496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results.
    Nakatsukasa K; Koyama H; Ouchi Y; Ono H; Sakaguchi K; Matsuda T; Kato M; Ishikawa T; Yamada K; Yoshimura M; Koizumi K; Sakurai T; Shigematsu H; Takahashi S; Taira S; Suzuki M; Narui K; Niikura N; Hasegawa Y; Miura D; Konishi E; Taguchi T;
    Breast Cancer; 2019 Jan; 26(1):106-112. PubMed ID: 30054855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Odanacatib treatment affects trabecular and cortical bone in the femur of postmenopausal women: results of a two-year placebo-controlled trial.
    Engelke K; Fuerst T; Dardzinski B; Kornak J; Ather S; Genant HK; de Papp A
    J Bone Miner Res; 2015 Jan; 30(1):30-8. PubMed ID: 24898537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AI-related BMD variation in actual practice conditions: A prospective cohort study.
    Rodríguez-Sanz M; Prieto-Alhambra D; Servitja S; Garcia-Giralt N; Garrigos L; Rodriguez-Morera J; Albanell J; Martínez-García M; González I; Diez-Perez A; Tusquets I; Nogués X
    Endocr Relat Cancer; 2016 Apr; 23(4):303-12. PubMed ID: 26911377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TBS and BMD at the end of AI-therapy: A prospective study of the B-ABLE cohort.
    María RS; Marta PM; Sonia S; Natalia GG; Tamara M; Ignasi T; Maria MG; Jaime RM; Adolfo DP; Joan A; Xavier N
    Bone; 2016 Nov; 92():1-8. PubMed ID: 27519968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer.
    Nogues X; Servitja S; Peña MJ; Prieto-Alhambra D; Nadal R; Mellibovsky L; Albanell J; Diez-Perez A; Tusquets I
    Maturitas; 2010 Jul; 66(3):291-7. PubMed ID: 20399042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of risedronate on hip structural geometry in chemotherapy-induced postmenopausal women with or without use of aromatase inhibitors: a 2-year trial.
    van Londen GJ; Perera S; Vujevich KT; Sereika SM; Bhattacharya R; Greenspan SL
    Bone; 2010 Mar; 46(3):655-9. PubMed ID: 19853678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of chemotherapy followed by aromatase inhibitors on bone health of women with ER-positive early breast cancer in real world clinical settings in Greece: Results of the POCHARBI trial conducted by the Hellenic Society of Breast Surgeons.
    Markopoulos C; Koukouras D; Venizelos V; Karyda I; Xepapadakis G; Misitzis J; Kalogerakos K; Poulakaki F; Natsiopoulos J; Zobolas V; Savidou C; Antonopoulou Z; Tzoracoleftherakis E
    Breast; 2016 Jun; 27():27-34. PubMed ID: 27212697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.
    Yonehara Y; Iwamoto I; Kosha S; Rai Y; Sagara Y; Douchi T
    J Obstet Gynaecol Res; 2007 Oct; 33(5):696-9. PubMed ID: 17845332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.